Literature DB >> 26992944

The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure.

Aziz Nazha1, Rami S Komrokji2, Guillermo Garcia-Manero3, John Barnard4, Gail J Roboz5, David P Steensma6, Amy E DeZern7, Katrina Zell4, Cassie Zimmerman1, Najla Al Ali2, Elias Jabbour3, Molly D Greenberg5, Hagop M Kantarjian3, Jaroslaw P Maciejewski1, Alan F List2, Mikkael A Sekeres8.   

Abstract

Entities:  

Keywords:  MDS; hypomethylating agent; prognostic models

Mesh：

Substances：

Year:  2016        PMID： 26992944      PMCID： PMC5013943          DOI： 10.3324/haematol.2015.140962

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Revised international prognostic scoring system for myelodysplastic syndromes.

Authors:  Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase
Journal:  Blood       Date:  2012-06-27       Impact factor: 22.113

2.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

3.  Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.

Authors:  Elias Jabbour; Guillermo Garcia-Manero; Nicolas Batty; Jenny Shan; Susan O'Brien; Jorge Cortes; Farhad Ravandi; Jean-Pierre Issa; Hagop Kantarjian
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

4.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

Authors:  Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

5.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors:  Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

6.  Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

Authors:  Thomas Prébet; Steven D Gore; Benjamin Esterni; Claude Gardin; Raphael Itzykson; Sylvain Thepot; François Dreyfus; Odile Beyne Rauzy; Christian Recher; Lionel Adès; Bruno Quesnel; C L Beach; Pierre Fenaux; Norbert Vey
Journal:  J Clin Oncol       Date:  2011-07-25       Impact factor: 44.544

7.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

8.  Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

Authors:  Hagop Kantarjian; Jean-Pierre J Issa; Craig S Rosenfeld; John M Bennett; Maher Albitar; John DiPersio; Virginia Klimek; James Slack; Carlos de Castro; Farhad Ravandi; Richard Helmer; Lanlan Shen; Stephen D Nimer; Richard Leavitt; Azra Raza; Hussain Saba
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860

Review 9.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

10.  Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.

Authors:  Hagop Kantarjian; Susan O'Brien; Farhad Ravandi; Jorge Cortes; Jianqin Shan; John M Bennett; Alan List; Pierre Fenaux; Guillermo Sanz; Jean-Pierre Issa; Emil J Freireich; Guillermo Garcia-Manero
Journal:  Cancer       Date:  2008-09-15       Impact factor: 6.860
View more
  16 in total

Review 1.  Making Sense of Prognostic Models in Chronic Myelomonocytic Leukemia.

Authors:  Aziz Nazha; Mrinal M Patnaik
Journal:  Curr Hematol Malig Rep       Date:  2018-10       Impact factor: 3.952

Review 2.  Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.

Authors:  Aziz Nazha; Rafael Bejar
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

3.  Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia.

Authors:  Brian Ball; Rami S Komrokji; Lionel Adès; Mikkael A Sekeres; Amy E DeZern; Lisa Pleyer; Norbert Vey; Antonio Almeida; Ulrich Germing; Thomas Cluzeau; Uwe Platzbecker; Steven D Gore; Pierre Fenaux; Thomas Prebet
Journal:  Blood Adv       Date:  2018-08-28

4.  Patient stratification in myelodysplastic syndromes: how a puzzle may become a map.

Authors:  Anne Sophie Kubasch; Uwe Platzbecker
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 5.  Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure.

Authors:  Hetty E Carraway
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

6.  Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system.

Authors:  Thomas Prebet; Pierre Fenaux; Norbert Vey
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941

Review 7.  Improving Prognostic Modeling in Myelodysplastic Syndromes.

Authors:  Aziz Nazha; Mikkael A Sekeres
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

Review 8.  Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.

Authors:  Natalie Uy; Abhay Singh; Steven D Gore; Thomas Prebet
Journal:  Expert Opin Pharmacother       Date:  2017-08-01       Impact factor: 3.889

Review 9.  Rethinking clinical trial endpoints in myelodysplastic syndromes.

Authors:  Mikkael A Sekeres; David P Steensma
Journal:  Leukemia       Date:  2019-01-30       Impact factor: 11.528

Review 10.  Prognosis in Myelodysplastic Syndromes: The Clinical Challenge of Genomic Integration.

Authors:  Tzu-Hua Chen-Liang
Journal:  J Clin Med       Date:  2021-05-11       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.